https://www.selleckchem.com/pr....oducts/polyethylenim
Conclusions In patients with heart failure and a preserved ejection fraction, empagliflozin produced a meaningful, early and sustained reduction in the risk and severity of a broad range of inpatient and outpatient worsening heart failure events. Clinical Trial Registration The registration identifier at ClinicalTrials.gov is NCT03057977.Background Observational and small randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Methods We conducted an inv
Like
Comment
Share
